Avantor Faces Securities Fraud Class Action; Investors Can Join by Dec 29
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Lawsuit Background: Glancy Prongay & Murray LLP announces that investors can join a securities fraud class action against Avantor, Inc. by December 29, 2025, alleging the company failed to disclose its weaker competitive position.
- Competitive Impact: The lawsuit claims that between March 5, 2024, and October 28, 2025, Avantor faced negative effects from increased competition, rendering the company's positive statements materially misleading and lacking a reasonable basis.
- Investor Losses: Affected investors are encouraged to participate in the lawsuit to seek compensation for losses incurred due to misleading statements, highlighting significant concerns regarding corporate governance and transparency.
- Legal Consultation Opportunity: Investors can contact the law firm for more information, indicating that legal avenues provide potential remedies for affected investors.
AVTR
$11.24+Infinity%1D
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 13.86 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.270
Low
12.00
Averages
13.86
High
17.00
Current: 11.270
Low
12.00
Averages
13.86
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
